

On the EU's General Pharmaceutical Legislation



EUCOPE sees the review as an opportunity to build a **future-proofed pharmaceutical framework** that **supports access to innovative therapies** and **builds an internationally competitive environment** that continues to promote research and development in Europe, which in turn allows the marketing of new technologies that reach patients.

EUCOPE's vision on how to improve the legislative framework:

- 1. Build a future-proof regulatory framework** to support the assessment and access to innovative technologies.
- 2. Maintain a robust and predictable incentive framework** to continue encouraging innovation and the development of novel health technologies.
- 3. Update the legislative framework** to ensure that the EU remains competitive on the international stage, encouraging the development, research and launch of therapies in the EU.

“The revision of the pharmaceutical legislative framework must be strengthened, accounting for hurdles faced by small and mid-sized pharmaceutical companies so that it can promote sustainable financing and the continued research and development of new technologies.”



Alexander Natz
Secretary General